ClinicalTrials.gg
CompletedNCT02957929Updated Sep 10, 2025

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

A Phase 1 interventional study of APX001 single IV dose and APX001 single oral dose 1 in Fungal Infection, sponsored by Basilea Pharmaceutica. Completed at 2 sites in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Mycoses with a site in Netherlands — 1 open to participants now, 1 under way, 1 of them phase 3. Mycoses · Netherlands.

Enrollment
5th of 10
46 · median 44
Started
2016
with 1 other
Phase 1
4 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
4 of 13
Basilea Pharmaceutica

Among the 13 studies in Mycoses with a site in Netherlands, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 1, and was the 8th registered.

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

Browse Mycoses studies →

Open to participants now

1 of the 13 studies in Mycoses with a site in Netherlands is open now. Recruiting first, the newest first:

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 24 Mycoses studies recruiting now, 13 (54%) set no upper age limit and 4 (17%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Mycoses with a site in Netherlands, or all of them as a file.
02

Study summary

This is a Phase l double-blind, placebo-controlled, randomized study to investigate the safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of APX001 administered intravenously and orally, followed by an evaluation of the safety, tolerability, pharmacokinetics and drug-drug interaction potential of multiple doses of APX001 administered orally.

03

Conditions studied

  • Fungal Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of must agree to avoid pregnancy during the study and to use at least 2 weeks before the start of the study until 3 months after the last dose of study drug.
  • Males with partner(s) of childbearing potential must agree to use appropriate barrier contraception from the screening period until 3 months after the last dose of study drug.
  • Screening hematology, clinical chemistry, coagulation and urinalysis consistent with overall good health.
  • No significantly abnormal findings on physical examination, and vital signs.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Any uncontrolled or active major systemic disease including, but not limited to: cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with potential.
  • History or presence of within the past year. Subjects who have been successfully treated with no recurrence of basal cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.
  • Use of prescription medication within 14 days prior to the first dose of study drug and throughout the study.
  • Use of non-prescription or over-the-counter medications within 7 days prior to the first dose of study drug and throughout the study.
  • Positive results on any of the following Screening laboratory tests: serum pregnancy test, urine alcohol test, urine drugs of abuse, surface antigen, antibody, and (HIV) antibody.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Cohort 1a, Period A

    single intravenous dose, crossover

    Drug: APX001 single IV dose · Drug: Matching placebo control

  • Experimental
    Cohort 1a, Period B

    single oral dose, crossover

    Drug: APX001 single oral dose 1 · Drug: Matching placebo control

  • Experimental
    Cohort 1a, Period C

    single oral dose

    Drug: APX001 single oral dose 2 · Drug: Matching placebo control

  • Experimental
    Cohort 1a, Period D

    single oral dose, crossover

    Drug: APX001 single oral dose 3 · Drug: Matching placebo control

  • Experimental
    Cohort 1b, Period E

    Single oral dose under fasted conditions, crossover

    Drug: APX001 single oral dose fasted · Drug: Matching placebo control

  • Experimental
    Cohort 1b, Period F

    Single oral dose under fed conditions, crossover

    Drug: APX001 single oral dose fed · Drug: Matching placebo control

  • Experimental
    Cohort 2

    Multiple oral doses

    Drug: APX001 multiple oral doses 1 · Drug: Matching placebo control

  • Experimental
    Cohort 3

    Multiple oral doses

    Drug: APX001 multiple oral doses 2 · Drug: Matching placebo control

  • Experimental
    Cohort 4

    Multiple oral doses in presence of CYP probe substrates

    Drug: APX001 single IV dose · Drug: APX001 multiple oral doses 3 · Drug: Cytochrome P450 substrates

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of single and multiple oral doses of APX001 as measured by adverse events (AEs), physical examinations (PE), vital signs (VS), laboratory safety tests, urinalysis and 12-lead electrocardiograms (ECG).

    Time frame: 21 days

Secondary outcomes

  1. Pharmacokinetics of single and multiple doses of APX001 as measured by maximum observed concentration (Cmax).

    Time frame: 21 days

  2. Pharmacokinetics of single and multiple dose of APX001 as measured by area under the curve (AUC).

    Time frame: 21 days

  3. Pharmacokinetics of single and multiple doses of APX001 as measured by terminal half life (t1/2).

    Time frame: 21 days

  4. Pharmacokinetics of single and multiple doses of APX001 as measured by volume of distribution (Vd).

    Time frame: 21 days

  5. Pharmacokinetics of single and multiple doses of APX001 as measured by elimination rate constant (Kel).

    Time frame: 21 days

  6. Pharmacokinetics of single and multiple doses of APX001 as measured by accumulation ratio.

    Time frame: 21 days

07

Study locations

2 sites
  • PRA Health Sciences (PRA) - Early Development Services (EDS)
    Groningen, 9728 NZ, Netherlands
  • PRA Health Sciences
    Groningen, Netherlands
08

References and documents

Publications

  • Hodges MR, Ople E, Wedel P, Shaw KJ, Jakate A, Kramer WG, Marle SV, van Hoogdalem EJ, Tawadrous M. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0162322. doi: 10.1128/aac.01623-22. Epub 2023 Mar 29. PubMed 36988461 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Apr 2017, 5 months.

Of 18 phase 1 interventional studies under Mycoses, half reached primary completion within 8 months of starting (the median); a quarter within 3 and three quarters within 13. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2016
First posted
Nov 8, 2016
StartActual
Oct 31, 2016
Primary completionActual
Apr 20, 2017
CompletionActual
Apr 20, 2017
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02957929
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Oct 31, 2016
Primary completion
Apr 20, 2017
Completion
Apr 20, 2017
Last update
Sep 10, 2025

Study contacts

Marc Engelhardt
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosmanogepix

Start the discussion